MENU

XTLB Stock XTL Biopharmaceuticals (XTLB, $1.32) price moved above its 50-day Moving Average on July 03, 2025

A.I.dvisor
at Tickeron.com
Loading...
XTLB - XTL Biopharmaceuticals Ltd
Moving Avg. signal
Bullish Trend
Odds of UP Trend
Tickeron
Moving Avg. signal
Price: $1.32
Daily change: +$0.12 (+10%)
Daily volume: 43.8K
Capitalization: $10.2M
Industry: Biotechnology
This price move could indicate a change in the trend, and may be a buy signal for investors. A.I.dvisor found 59 similar cases, and were successful. Based on this data, the odds of success are

XTLB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 20, 2025

XTLB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where XTLB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where XTLB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on XTLB as a result. In of 125 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XTLB just turned positive on June 24, 2025. Looking at past instances where XTLB's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

XTLB moved above its 50-day moving average on July 03, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XTLB advanced for three days, in of 184 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.140) is normal, around the industry mean (16.666). P/E Ratio (0.000) is within average values for comparable stocks, (58.763). XTLB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (20.619) is also within normal values, averaging (269.614).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XTLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTLB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics to treat hepatitis and other infectious diseases, using human antibodies and synthetic chemicals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5 Badner Street
Phone
+972 36116600
Employees
4
Web
https://www.xtlbio.com